Subconjunctival high dose plasminogen activator in rabbit filtration surgery

Area of Science:

• Ophthalmology
• Surgical Innovation
• Fibrosis Research

Background:

• Glaucoma filtration surgery aims to reduce intraocular pressure.
• Fibroblastic proliferation and subconjunctival fibrosis are primary causes of surgical failure.
• Reduced aqueous humor outflow through the surgical bleb leads to decreased surgical efficacy.

Purpose of the Study:

• To evaluate the efficacy of recombinant tissue plasminogen activator (t-PA) in reducing episcleral fibrosis at the surgical bleb site.
• To assess the safety and potential complications associated with t-PA application in a glaucoma surgery model.

Main Methods:

• A masked, placebo-controlled pilot study was conducted using New Zealand white rabbits.
• Three treatment groups received either balanced salt solution, an inert gel vehicle, or a gel vehicle with t-PA (1 mg/ml).
• Histologic sections of the surgical bleb site were analyzed using computer-assisted measurements to quantify episcleral fibrosis.

Main Results:

• A statistically significant decrease in episcleral fibrosis was observed in the t-PA treated group compared to control groups (p < 0.05).
• No significant effect of t-PA on intraocular pressure was detected.
• No clinical evidence of toxicity or adverse healing complications was noted in the t-PA group.

Conclusions:

• Recombinant tissue plasminogen activator (t-PA) demonstrates potential in mitigating episcleral fibrosis following glaucoma filtration surgery.
• t-PA may offer a novel therapeutic approach to enhance the long-term success of glaucoma surgeries.
• Further investigation is warranted to explore t-PA's clinical applicability and long-term effects in glaucoma patients.